Name: Jiangxi Biological Products Research Institute Co., Ltd.
Address: National Jinggangshan Economic and Technological Development Zone, Ji'an City, Jiangxi Province
In 1969, the Jiangxi Branch of the Shanghai Institute of Biological Products of the Ministry of Health was formally established to produce and research anti-toxin and vaccine biological products.
In 1971, it was renamed Jiangxi Institute of Biological Products.
In 1994, through the inspection and acceptance of the Ministry of Health, the "Pharmaceutical Manufacturers License" was obtained.
In 1995, the production approval number of three specifications of human rabies vaccine and refined tetanus antitoxin was obtained, and the Ji'an Experimental Animal Center was established.
In 1998, the human rabies vaccine and tetanus antitoxin were awarded the Excellent New Product Certificate of Jiangxi Province.
In 2002, the company successfully reformed and changed state-owned shares into limited liability companies.
In 2004, the company changed its GMP in different places, and moved to the Jinggangshan Economic and Technological Development Zone in Ji'an City. In the same year, it passed the drug GMP certification.
In 2005, the company established the largest domestic immune horse plasma production base in Zhangye City, Gansu Province.
In 2005, the company obtained the certificate of high-tech enterprise certification.
In 2007, the company hosted a national seminar on the quality of anti-toxin and immune serum production.
In 2012, the company established more than 200,000 mu of the world's largest horse breeding and breeding base in Weinan City, Gansu Province.
In 2013, the company built a new production line of anti-toxin and immune serum in China, and passed the 2010 version of the drug GMP certification.
In 2015, the company established the first domestic immune plasma plasma purification workshop in Zhangye City, Gansu Province according to GMP requirements.
In December 2017, the company was restructured from a limited liability company into a company limited by shares.